Arena Pharmaceuticals

We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. Our internally discovered drug for chronic weight management, BELVIQ ® (lorcaserin HCl), was approved by the FDA for marketing in the United States to adults who are overweight with a comorbidity or obese, and was made available to patients by our collaborator, Eisai, by prescription in June 2013. In February 2015, BELVIQ was also approved for weight management in South Korea and will be marketed by our collaborator, Ildong.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1977
Size (employees)
228 (est)
Arena Pharmaceuticals was founded in 1977 and is headquartered in San Diego, US

Arena Pharmaceuticals Office Locations

Arena Pharmaceuticals has offices in San Diego, Zofingen
San Diego, US (HQ)
6154 Nancy Ridge Drive
Zofingen, CH
4 Untere Brühlstrasse

Arena Pharmaceuticals Metrics

Arena Pharmaceuticals Financial Metrics

Revenue (2016)

$124 m

Revenue growth (2015-16), %

223%

Gross profit

$114.7 m

Gross profit margin (2016), %

93%

Net income (2016)

($22.9 m)

Market capitalization (21-Mar-2017)

$355.3 m

Closing share price (21-Mar-2017)

$1.5

Cash (31-Dec-2016)

$90.7 m
Arena Pharmaceuticals's current market capitalization is $355.3 m.
Arena Pharmaceuticals's revenue was reported to be $124 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$81.4 m$37 m$38.3 m$124 m

Revenue growth, %

(55%)4%223%

Cost of goods sold

$1.8 m$6.4 m$8.6 m$9.3 m

Gross profit

$79.6 m$30.6 m$29.7 m$114.7 m

Gross profit Margin, %

98%83%78%93%

Operating expense total

$104.3 m$135.9 m$132.9 m$141.1 m

EBIT

($22.9 m)($105.3 m)($103.2 m)($17.1 m)

EBIT margin, %

(28%)(285%)(269%)(14%)

Interest expense

$7.1 m$6.9 m$6.8 m$6.5 m

Interest income

$89 k$83 k$158 k$290 k

Net Income

($19.4 m)($60.5 m)($108 m)($22.9 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$221.9 m$163.2 m$156.2 m$90.7 m

Accounts Receivable

$10.6 m$3.7 m$4.9 m$20.2 m

Inventories

$3.6 m$4.1 m$4.2 m$2.3 m

Current Assets

$248.8 m$181.9 m$174.8 m$119.9 m

Total Assets

$339.8 m$276.4 m$256.8 m$169 m

Accounts Payable

Current Liabilities

$70.7 m$67.4 m$49.9 m$63.9 m

Additional Paid-in Capital

$1.3 b$1.3 b$1.4 b$1.4 b

Retained Earnings

($1.2 b)($1.3 b)($1.4 b)($1.4 b)

Total Equity

$91.9 m$47.3 m$53.5 m$40.4 m

Financial Leverage

3.7 x5.8 x4.8 x4.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($19.4 m)($60.5 m)($108 m)($22.9 m)

Depreciation and Amortization

$7.7 m$8.7 m$9.8 m$9.1 m

Accounts Receivable

($4.5 m)$6.4 m($1.4 m)($16 m)

Inventories

($6.1 m)$870 k$1.9 m$3.2 m

Accounts Payable

Cash From Operating Activities

$72.8 m($101.4 m)($98.1 m)($62.1 m)

Cash From Investing Activities

($8.7 m)$40.9 m($8.2 m)($750 k)

Cash From Financing Activities

$1.7 m$3.2 m$101.1 m($2.3 m)

Interest Paid

$7 m$6.8 m$6.6 m$6.3 m

Arena Pharmaceuticals Market Value History

Arena Pharmaceuticals Company Life

You may also be interested in